MedTrace Logo

Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers

NCT00586625 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 861

Last updated 2013-02-15

Study results available
· View outcomes & findings →

Summary

Safety study for bepotastine besilate ophthalmic solution in normal volunteers

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

Bepreve

One drop, both eyes, twice a day

DRUG

Placebo

One drop, both eyes, twice a day

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    lead INDUSTRY

Principal Investigators

  • Tim McNamara, PharmD · ISTA Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-05-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00586625 on ClinicalTrials.gov